BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. The Company, through its wholly owned subsidiaries, BioSyent Pharma Inc., and BioSyent Pharma International Inc., sources, acquires or in-licenses and further develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary, operates the Company’s business marketing biologically and health friendly non-chemical insecticides. The Company’s products include Combogesic, Cathejell, FeraMAX Pd Therapeutic 150, FeraMAX Pd Maintenance 45, FeraMAX Pd Powder 15, Gelclair, Inofolic, Proktis-M, RepaGyn, and Tibella. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia. FeraMAX Pd Maintenance 45 is a chewable supplement with iron plus vitamin B12 and vitamin C for the prevention of iron deficiency anemia.
Follow-Up Questions
BIOYF 주식의 가격 성능은 어떻습니까?
BIOYF의 현재 가격은 $7.98이며, 전 거래일에 decreased 0% 하였습니다.
BioSyent Inc의 주요 사업 주제나 업종은 무엇입니까?
BioSyent Inc은 Pharmaceuticals 업종에 속하며, 해당 부문은 Health Care입니다
BioSyent Inc의 시가총액은 얼마입니까?
BioSyent Inc의 현재 시가총액은 $89.8M입니다
BioSyent Inc는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 3명의 분석가가 BioSyent Inc에 대한 분석 평가를 실시했으며, 이는 2명의 강력한 매수, 4명의 매수, 1명의 보유, 0명의 매도, 그리고 2명의 강력한 매도를 포함합니다
